Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concernArticle Published on 2022-10-012022-11-15 Journal: ESMO open [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] anti-SARS-CoV-2 Anti-spike antibody BNT162b2 BNT162b2 anti-SARS-CoV-2 vaccine BNT162b2 vaccine booster Cancer cancer patient cell-mediated immune Cellular immune response Concentration COVID-19 delta variant dose evaluated follow-up period highest highlight Hospitalization humoral Immunoglobulin Infection interferon-γ interquartile range longitudinal cohort study lowest median Messenger RNA Neutralizing Neutralizing activity neutralizing antibody of BNT162b2 omicron Oxygen therapy Patient positive response reduced reduction in required SARS-CoV-2 serum Seven solid tumor subject the SARS-CoV-2 third dose Treatment triggering Vaccine variant variants of concern VOCs were measured were used whole blood sample wild-type strain [DOI] 10.1016/j.esmoop.2022.100574 PMC 바로가기
Characterization of coagulopathy and outcomes in cancer patients with severe COVID -19 illness: Longitudinal changes in hospitalized cancer patientsArticle Published on 2022-10-012022-11-15 Journal: Cancer Medicine [Category] COVID19(2023년), SARS, 바이오마커, [키워드] 1:1 Anderson blood cell count Cancer cancer patient Cancer patients CBC center change changes in characterization clinical clinical observations Coagulopathy Complete correlated COVID COVID-19 COVID-19 illness COVID-19 patient Critical CRP death disease elevated feature fibrinogen FIVE future risk had more help hematological hematological cancer Hospital admission Hospital stay Hospitalization Hospitalized IL-6 inflammatory markers interleukin-6 lack longitudinal Lymphocyte count management measure mechanical ventilation mechanism Mortality neutrophil Non-COVID-19 outcome outcomes Peripheral blood Platelet prognostic Prognostic factor required Retrospective analysis risk Risk assessment Serum ferritin severe COVID-19 illness Stratification survival thrombosis Thrombotic complications unique viral infection with COVID-19 [DOI] 10.1002/cam4.4753 PMC 바로가기
Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for useArticle Published on 2022-10-012022-11-15 Journal: European Journal of Clinical Pharmacology [Category] COVID19(2023년), SARS, 신약개발, 치료제, [키워드] absence antidepressant antidepressants antiviral drug approved article benefit Care Clinical outcome clinical trial coronavirus COVID COVID-19 database death decrease drug effort Hospitalization Infection infections information inhibit inhibitor Intensive intubation methodological flaws Mild-to-moderate mortality rates Novel coronavirus pandemic patients receptor Redirection reduce reported repositioning Repositioning. Research risk SARS-CoV-2 SciELO selective Serotonin shown specific treatment therapeutic intervention Toxicity treat Treatment viral titer was performed [DOI] 10.1007/s00228-022-03372-5 PMC 바로가기
Clinician Perspectives on Monoclonal Antibody Treatment for High-Risk Outpatients with COVID-19: Implications for Implementation and Equitable AccessArticle Published on 2022-10-012022-11-15 Journal: Journal of General Internal Medicine [Category] 진단, [키워드] access acute care Care clinical setting clinical settings clinician Complete COVID-19 death diffusion diffusion of innovations dissemination dissemination and implementation eligibility criteria eligible Eligible patients Evidence facilitate Factor feasibility feasible health systems Hospitalization identify indicated knowledge mAb mAbs management monoclonal antibody MOST Outpatient Patient patients with COVID-19 primary care public health reduce referral. reported respondent survey therapy Treatment with COVID-19 [DOI] 10.1007/s11606-022-07702-2 PMC 바로가기
Evaluation of the efficacy of oral nano-silymarin formulation in hospitalized patients with COVID-19: A double-blind placebo-controlled clinical trialArticle Published on 2022-10-012022-11-15 Journal: Phytotherapy research : PTR [Category] COVID19(2023년), SARS, 치료제, [키워드] alanine aminotransferase Anti-viral Antiviral assigned baseline clinical trial Concomitant COVID-19 cytokine release Cytokine release syndrome Dexamethasone dosage double-blind Effect effective Effectiveness Efficacy Evidence follow-up period gel Hospitalization hospitalized patient Laboratory Laboratory parameters lack liver enzyme management outbreak pandemic participant Patient patients with COVID-19 placebo group placebo-controlled clinical trial receiving Remdesivir sample sizes SARS-CoV-2 significant difference significantly silymarin Symptom the placebo group therapeutic strategy Treatment treatment group two group viral disease were assessed [DOI] 10.1002/ptr.7537 PMC 바로가기
Real-life Evidence of Lower Lung Virulence in COVID-19 Inpatients Infected with SARS-CoV-2 Omicron Variant Compared to Wild-Type and Delta SARS-CoV-2 PneumoniaArticle Published on 2022-10-012022-11-16 Journal: Lung [Category] COVID19(2023년), SARS, 변종, [키워드] adult subject ambient animal model ARDS better respiratory function blood gas analysis Comorbidities consolidation COVID-19 Delta described evidence of explain hospital Hospitalization Immunity in vitro Infection Inpatient Italy less Lineage Lower lower mortality lower risk lung parenchyma observation omicron other variant Pneumonia preliminary finding replication capacity respiratory airway Respiratory failure SARS-CoV-2 severe respiratory failure Turin variants of concern virulence wild type [DOI] 10.1007/s00408-022-00566-7 PMC 바로가기
A novel evidence-based predictor tool for hospitalization and length of stay: insights from COVID-19 patients in New York cityArticle Published on 2022-10-012023-07-09 Journal: Internal and Emergency Medicine [Category] COVID19(2023년), [키워드] Coronavirus disease 2019 (COVID-19) Hospitalization Length of stay Predictor model. [DOI] 10.1007/s11739-022-03014-9 PMC 바로가기
Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surgeArticle Published on 2022-09-302022-11-15 Journal: Journal of Antimicrobial Chemotherapy [Category] SARS, 진단, [키워드] 95% CI all-cause mortality B.1.1.529 clinical trial Cohort component control patient COVID-19 COVID-19 outpatient Effectiveness evaluate events Hospitalization Hospitalized incidence less likelihood no difference omicron Outpatient positive Primary outcome receive receiving reduction in Remdesivir retrospective cohort study risk SARS-CoV-2 secondary outcome severe COVID-19 significantly significantly lower Symptom symptom onset the primary endpoint therapy treated [DOI] 10.1093/jac/dkac256 PMC 바로가기
Effectiveness of a Second COVID-19 Vaccine Booster Dose Against Infection, Hospitalization, or Death Among Nursing Home Residents – 19 States, March 29-July 25, 2022Article Published on 2022-09-302022-11-16 Journal: Morbidity and Mortality Weekly Report [Category] SARS, 변종, [키워드] Against Analysis B.1.1.529 booster booster dose booster doses cause collected Committee Community COVID-19 COVID-19 infection COVID-19 vaccine death deaths dose Effectiveness Endpoint evaluated facility Follow-up home Hospitalization Immunocompromised monovalent vaccine morbidity and mortality mRNA Nursing omicron outcome outcomes Practice predominant Prevent provided resident routine care SARS-CoV-2 second severe COVID-19 vaccination Vaccine variant variants virus with COVID-19 [DOI] 10.15585/mmwr.mm7139a2 PMC 바로가기
Multiple Post-SARS-COV2 Infectious Complications in Kidney Transplant RecipientArticle Published on 2022-09-292022-11-15 Journal: Medicina [Category] SARS, 진단, [키워드] Candida Clostridioides difficile infection Complication Course COVID-19 infection diagnosed dialysis disease glomerular filtration rate Hemodialysis hospital Hospitalization Infection infections kidney Kidney transplantation Klebsiella pneumoniae Mild Modification multi-pathogenic infections. multiorgan failure Multiple neutralizing antibody occurred oral candidiasis Patient recipient required SARS-CoV-2 SARS-COV-2 infection Severe infection Streptococcus the disease the patient therapy Transplant Urinary tract vaccinated against COVID-19 [DOI] 10.3390/medicina58101370 PMC 바로가기